Conference Coverage: ASH 2022 – Focus on Multiple Myeloma

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding multiple myeloma.

December 14, 2022


Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ, USA

Faculty Members

Keith Stewart, MB, ChB, MBA
Princess Margaret Cancer Centre, Toronto, ON, Canada

Gareth Morgan, MD, PhD, FRCP, FRCPath
Perlmutter Cancer Center, New York, NY, USA

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, USA

Suzanne Lentzsch, MD, PhD
Columbia University Irving Medical Center, New York, NY, USA

Peter Voorhees, MD
Levine Cancer Institute, Charlotte, NC, USA

Maria-Victoria Mateos, MD, PhD
University of Salamanca, Spain

Hermann Einsele, MD, FRCP
University of Würzburg, Germany

Sample Report

Start discovering the insights

View Report


  • Clinical experts from across the world will discuss global perspectives on current treatment strategies and emerging therapies in multiple myeloma derived from ASH 2022 data
  • The goal of the expert panel will be to critique and debate new evidence in multiple myeloma and gain strategic insight into the most impactful abstracts from the ASH meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.